Read by QxMD icon Read

International Journal of Neuropsychopharmacology

Richard S E Keefe, George Nomikos, Wei Zhong, Michael Cronquist Christensen, William Jacobson
Background: We evaluated vortioxetine's effects on functional capacity in demographic and clinical subgroups of patients with major depressive disorder. Methods: This was an exploratory analysis of the CONNECT study (NCT01564862) that evaluated changes in functional capacity using University of California San Diego Performance-based Skills Assessment (UPSA) data, categorized by sex, age, education, employment status, and baseline disease severity (Montgomery-Åsberg Depression Rating Scale [MADRS], Clinical Global Impressions-Severity of Illness [CGI-S])...
March 12, 2018: International Journal of Neuropsychopharmacology
Dean F Wong, Hiroto Kuwabara, Andrew G Horti, Joshua M Roberts, Ayon Nandi, Nicola Casella, James Brasic, Elise M Weerts, Kelly Kitzmiller, Jenny A Phan, Lorena Gapasin, Akira Sawa, Heather Valentine, Gary Wand, Noble George, Michael McDonald, William Kem, Robert Freedman, Albert Gjedde
Background: The α7 nicotinic acetylcholine receptor (nAChR) increasingly has been implicated in normal brain physiology, as well as in neuropsychiatric disorders. The highly cortical distribution of α7-nAChR suggests a role in cognition. Methods: We expanded the first-in-human PET imaging of α7-nAChR with [18F]ASEM from five to 21 healthy non-smoking volunteers and added a feasibility study in six male patients with schizophrenia. Study aims included 1) confirmation of test-retest reproducibility of [18F]ASEM binding, 2) demonstration of specificity by competition with DMXB-A, an α7-nAChR partial agonist, 3) estimation of [18F]ASEM binding potentials and α7-nAChR density in vivo in humans, and 4) demonstrating the feasibility of studying α7-nAChR as a target for schizophrenia...
March 7, 2018: International Journal of Neuropsychopharmacology
Fenghua Chen, Jibrin Danladi, Maryam Ardalan, Betina Elfving, Heidi K Müller, Gregers Wegener, Connie Sanchez, Jens R Nyengaard
Background: Preclinical studies have indicated that antidepressant effect of vortioxetine involves increased synaptic plasticity and promotion of spine maturation. Mitochondria dysfunction may contribute to the pathophysiological basis of major depressive disorder. Taking into consideration that vortioxetine increases spine number and dendritic branching in hippocampus CA1 faster than fluoxetine, we hypothesize that new spines induced by vortioxetine can rapidly form functional synapses by mitochondrial support, accompanied by increased brain-derived neurotrophic factor (BDNF)-signaling...
March 5, 2018: International Journal of Neuropsychopharmacology
Noriko Kudo, Hidenaga Yamamori, Tamaki Ishima, Kiyotaka Nemoto, Yuka Yasuda, Michiko Fujimoto, Hirotsugu Azechi, Tomihisa Niitsu, Shusuke Numata, Manabu Ikeda, Masaomi Iyo, Tetsuro Ohmori, Masaki Fukunaga, Yoshiyuki Watanabe, Kenji Hashimoto, Ryota Hashimoto
Background: An imbalance in the inflammatory tumor necrosis factor (TNF) system, including soluble tumor necrosis factor receptor 2 (sTNFR2), may contribute to the pathophysiology of schizophrenia. Methods: We measured the plasma levels of sTNFR2 in 256 healthy controls and 250 patients with schizophrenia including antipsychotic drug-free patients and treatment-resistant patients. We also explored the possible association between plasma sTNFR2 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition (WAIS-Ⅲ), the Wechsler Memory Scale-Revised (WMS-R), and the Rey Auditory Verbal Learning Test (AVLT)...
February 24, 2018: International Journal of Neuropsychopharmacology
Chunting Zhu, Min Liang, Yingchun Li, Xuejiao Feng, Juan Hong, Rong Zhou
Background: Prenatal stress is considered a risk factor for anxiety disorder. Downregulation in the expression of GABAergic gene, that is, glutamic acid decarboxylase 67, associated with DNA methyltransferase overexpression in GABAergic neurons has been regarded as a characteristic component of anxiety disorder. Prenatal stress has an adverse effect on the development of the basolateral amygdala, which is a key region in anxiety regulation. The aim of this study is to analyze the possibility of epigenetic alterations of GABAergic neurons in the basolateral amygdala participating in prenatal stress-induced anxiety...
February 20, 2018: International Journal of Neuropsychopharmacology
Chiara C Bortolasci, Briana Spolding, Edward Callaly, Sheree Martin, Bruna Panizzutti, Srisaiyini Kidnapillai, Timothy Connor, Kyoko Hasebe, Mohammadreza Mohebbi, Olivia M Dean, Sean L McGee, Seetal Dodd, Laura Gray, Michael Berk, Ken Walder
Background: Bipolar disorder (BD) is a mental health condition with progressive social and cognitive function disturbances. Most patients' treatments are based on polypharmacy, but with no biological basis and little is known of the drugs' interactions. The aim of this study was to analyse the effects of lithium, valproate, quetiapine and lamotrigine, and the interactions between them, on markers of inflammation, bioenergetics, mitochondrial function and oxidative stress in neuron-like cells (NT2) and microglial cells...
February 19, 2018: International Journal of Neuropsychopharmacology
Daniela Laricchiuta, Diego Andolina, Francesco Angelucci, Francesca Gelfo, Erica Berretta, Stefano Puglisi-Allegra, Laura Petrosini
Background: Approach system considered a motivational system that activates reward-seeking behavior is associated with exploration/impulsivity, whereas avoidance system considered an attentional system that promotes inhibition of appetitive responses is associated with active overt withdrawal. Approach and avoidance dispositions are modulated by distinct neurochemical profiles and synaptic patterns. However, the precise working of neurons and trafficking of molecules in the brain activity predisposing to approach and avoidance are yet unclear...
February 17, 2018: International Journal of Neuropsychopharmacology
Martin Hadamitzky, Arne Herring, Julia Kirchhof, Ivo Bendix, Matthew J Haight, Kathy Keyvani, Laura Lückemann, Meike Unteroberdörster, Manfred Schedlowski
Background: Clinical data indicate that therapy with small-molecule immunosuppressive drugs is frequently accompanied by an incidence rate of neuropsychiatric symptoms. In the current approach, we investigated in rats whether repeated administration of rapamycin (RAPA), reflecting clinical conditions of patients undergoing therapy with this mTOR inhibitor, precipitates changes in neurobehavioral functioning. Methods: Male adult Dark Agouti rats were daily treated with intraperitoneal injections of RAPA (1, 3 mg/kg) or vehicle for eight days...
February 15, 2018: International Journal of Neuropsychopharmacology
Matthijs G Bossong, Robin Wilson, Elizabeth Appiah-Kusi, Philip McGuire, Sagnik Bhattacharyya
Background: Dysfunctional reward processing is associated with a number of psychiatric disorders, such as addiction and schizophrenia. It is thought that reward is regulated mainly by dopamine transmission in the ventral striatum. Contemporary animal models suggest that striatal dopamine concentrations and associated behaviours are related to glutamatergic functioning in the ventral hippocampus. However, in humans the association between reward-related ventral striatal response and hippocampal glutamate levels is unclear...
February 10, 2018: International Journal of Neuropsychopharmacology
Mariam M Youssef, Mark D Underwood, Yung-Yu Huang, Shu-Chi Hsiung, Yan Liu, Norman R Simpson, Mihran J Bakalian, Gorazd B Rosoklija, Andrew J Dwork, Victoria Arango, J John Mann
Background: Brain-derived neurotrophic factor (BDNF) is implicated in the pathophysiology of major depressive disorder (MDD) and suicide. Both are partly caused by early life adversity (ELA) and ELA reduces BDNF protein levels. This study examines the association of BDNF Val66Met polymorphism and brain BDNF levels with depression and suicide. We hypothesized that both MDD and ELA would be associated with the Met allele and lower brain BDNF levels. Such an association would be consistent with low BDNF mediating the effect of ELA on adulthood suicide and MDD...
February 8, 2018: International Journal of Neuropsychopharmacology
Andy Forbes, Mary Hobart, John Ouyang, Lily Shi, Stephanie Pfister, Mika Hakala
Background: Brexpiprazole is a serotonin-dopamine activity modulator with efficacy in acute schizophrenia and relapse prevention. The aim of this Phase 3, multicenter study was to assess the long-term safety, tolerability, and efficacy of treatment with brexpiprazole flexible-dose 1-4 mg/day. Methods: Patients rolled over into this 52-week open-label study (amended to 26 weeks towards the end) from three randomized, double-blind, placebo-controlled Phase 3 studies...
February 3, 2018: International Journal of Neuropsychopharmacology
Bhaskar Roy, Qingzhong Wang, Yogesh Dwivedi
Background: Recent emergence of long non-coding RNAs (lncRNAs) in regulating gene expression and thereby modulating physiological functions in brain has manifested their possible role in psychiatric disorders. In this study, the roles of lncRNAs in susceptibility and resiliency to develop stress-induced depression and their response to antidepressant treatment were examined. Methods: Microarray based transcriptome-wide changes in lncRNAs was determined in hippocampus of male Holtzman rats who showed susceptibility (learned helpless; LH) or resiliency (non-learned helpless; NLH) to develop depression...
January 30, 2018: International Journal of Neuropsychopharmacology
Jing Wang, Yuwei Jia, Guodong Li, Biao Wang, Ting Zhou, Li Zhu, Teng Chen, Yanjiong Chen
Background: The altered expression and function of dopamine receptor D3 (D3R) in patients and animal models have been correlated with depression disease severity. However, the morphological alterations and biological effects of D3R in the brain after inflammation-induced depressive-like behavior remain elusive. Methods: In the present study, we ascertained the changes of D3R expression in the brain regions after depressive-like behavior induced by peripheral administration of lipopolysaccharide (LPS)...
January 30, 2018: International Journal of Neuropsychopharmacology
Xiao Wang, Kristina Sundquist, Karolina Palmér, Anna Hedelius, Ashfaque Memon, Jan Sundquist
Background: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that has been associated with various psychiatric disorders. MicroRNA-451a (miR-451a) can directly target MIF and down-regulate its expression in cells. However, the role of MIF and miR-451a in psychiatric patients treated with psychotherapeutic interventions is unknown. In this study, our aim was to investigate levels of MIF and its regulating miR-451a in patients with depression, anxiety or stress- and adjustment disorders who underwent mindfulness-based therapy or treatment as usual (TAU)...
January 24, 2018: International Journal of Neuropsychopharmacology
Haruko Kinoshita, Naoya Nishitani, Yuma Nagai, Chihiro Andoh, Nozomi Asaoka, Hiroyuki Kawai, Norihiro Shibui, Kazuki Nagayasu, Hisashi Shirakawa, Takayuki Nakagawa, Shuji Kaneko
Background: Ketamine rapidly elicits antidepressive effects in humans and mice, in which serotonergic activity is involved. Although α4β2 nicotinic acetylcholine receptor (α4β2 nAChR) in the dorsal raphe nucleus (DRN) plays a key role in the ketamine-induced prefrontal serotonin release, the source of cholinergic afferents and its role are unclear. Methods: Prefrontal serotonin levels after ketamine injection were measured by microdialysis in rats. Electrolytic lesion of pedunculopontine tegmental nucleus (PPTg) and laterodorsal tegmental nucleus (LDTg) was made with constant direct current...
January 23, 2018: International Journal of Neuropsychopharmacology
Amane Tateno, Takeshi Sakayori, Woo-Chan Kim, Kazuyoshi Honjo, Haruo Nakayama, Ryosuke Arakawa, Yoshiro Okubo
Background: Blockade of D3 receptor, a member of the dopamine D2-like receptor family, has been suggested as a possible medication for schizophrenia. Blonanserin has high affinity in vitro for D3 as well as D2 receptors. We investigated whether a single dose of 12 mg blonanserin, which was within the daily clinical dose range (i.e., 8-24 mg) for the treatment of schizophrenia, occupies D3 as well as D2 receptors in healthy subjects. Methods: Six healthy males (mean 35...
January 13, 2018: International Journal of Neuropsychopharmacology
Patricia Di Ciano, Rachel F Tyndale, Esmaeil Mansouri, Christian S Hendershot, Alan A Wilson, Dina Lagzdins, Sylvain Houle, Isabelle Boileau, Bernard Le Foll
Background: Identifying the biological basis of smoking cessation success is of growing interest. The rate of nicotine metabolism, measured by the nicotine metabolite ratio (NMR), affects multiple aspects of nicotine dependence. Fast nicotine metabolizers (FM) tend to smoke more, experience more withdrawal and craving and have lower cessation rates as compared to slow metabolizers (SM). The NMR predicts treatment response, and differences in brain activation between FM and SM have been reported in fMRI studies...
January 13, 2018: International Journal of Neuropsychopharmacology
David D Aguilar, Andrea Giuffrida, Daniel J Lodge
Background: Epidemiological studies recognize cannabis intake as a risk factor for schizophrenia, yet the majority of adolescents who use marijuana do not develop psychosis. Similarly, the abuse of synthetic cannabinoids poses a risk for psychosis. For these reasons, it is imperative to understand the effects of adolescent cannabinoid exposure in susceptible individuals. Method: We have recently developed a novel rodent model of schizophrenia susceptibility, the F2 MAM rat, where only a proportion (~40%) of rats display a schizophrenia-like phenotype...
January 10, 2018: International Journal of Neuropsychopharmacology
Shigeyuki Chaki
No abstract text is available yet for this article.
December 26, 2017: International Journal of Neuropsychopharmacology
Rosalba Satta, Briana Certa, Donghong He, Amy W Lasek
Background: Females are more vulnerable to developing cocaine addiction compared with males, a phenomenon that may be regulated by the steroid hormone 17β-estradiol (E2). E2 enhances cocaine reward as measured by the conditioned place preference (CPP) test. It is currently not known which estrogen receptor is involved or the neuroanatomical locations in which estrogen receptors act to enhance cocaine responses. The purpose of this study was to determine if the estrogen receptors ERαand ERβ regulate cocaine CPP in mice and whether they act in the nucleus accumbens (Acb), a brain region critically involved in the development of cocaine abuse...
December 23, 2017: International Journal of Neuropsychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"